Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
PTGX Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-79.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
19.50%
PTGX Stock Analysis
PTGX
PE Ratio:
PTGX
PEG Ratio:
Not Available
PTGX
Forward EPS Growth (12 month):
0.00%
PTGX
PS Ratio:
82.8
PTGX
PSG Ratio:
-1.1
PTGX
Forward Revenue Growth (12 month):
-73.40%
PTGX Articles
No data was found